OT J002656.6+284933 (CSS101212:002657+284933): An SU UMa-Type Dwarf Nova with Longest Superhump Period

We observed the 2016 outburst of OT J002656.6+284933 (CSS101212:002657+284933) and found that it has the longest recorded [0.13225(1) d in average] superhumps among SU UMa-type dwarf novae. The object is the third known SU UMa-type dwarf nova above the period gap. The outburst, however, was unlike ordinary long-period SU UMa-type dwarf novae in that it showed two post-outburst rebrightenings. It showed superhump evolution similar to short-period SU UMa-type dwarf novae. We could constrain the mass ratio to less than 0.15 (most likely between 0.10 and 0.15) by using superhump periods in the early and post-superoutburst stages. These results suggest the possibility that OT J002656.6+284933 has an anomalously undermassive secondary and it should have passed a different evolutionary track from the standard one.Comment: 6 pages, 3 figures, accepted for publication in PASJ (Letters), Note added in proof has been added. Supplementary Information (si.pdf) is available in the source fil

Komplex molekuláris genetikai vizsgálati algoritmus myeloproliferativ neoplasiák diagnosztikájában

Introduction: Mutations in Janus kinase 2, calreticulin and thrombopoietin receptor genes have been identified in the genetic background of Philadelphia chromosome negative, "classic" myeloproliferative neoplasms. Aim: The aim of the authors was to identify driver mutations in a large myeloproliferative cohort of 949 patients. Method: A complex array of molecular techniques (qualitative and quantitative allele-specific polymerase chain reactions, fragment analyzes, high resolution melting and Sanger sequencing) was applied. Results: All 354 patients with polycythemia vera carried Janus kinase 2 mutations (V617F 98.6%, exon 12: 1.4%). In essential thrombocythemia (n = 468), the frequency of V617F was 61.3% (n = 287), that of calreticulin 25.2% (n = 118), and that of thrombopoietin receptor mutations 2.1% (n = 10), while 11.3% (n = 53) were triple-negative. Similar distribution was observed in primary myelofibrosis (n = 127): 58.3% (n = 74) V617F, 23.6% (n = 30) calreticulin, 6.3% (n = 8) thrombopoietin receptor mutation positive and 11.8% (n = 15) triple-negative. Conclusions: The recent discovery of calreticulin gene mutations led to definite molecular diagnostics in around 90% of clonal myeloproliferative cases. Orv. Hetil., 2014, 155(52), 2074-2081

Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations

Somatic insertions/deletions in the calreticulin gene have recently been discovered to be causative alterations in myeloproliferative neoplasms. A combination of qualitative and quantitative allele-specific polymerase chain reaction, fragment-sizing, high resolution melting and Sanger-sequencing was applied for the detection of three driver mutations (in Janus kinase 2, calreticulin and myeloproliferative leukemia virus oncogene genes) in 289 cases of essential thrombocythemia and 99 cases of primary myelofibrosis. In essential thrombocythemia, 154 (53%) Janus kinase 2 V617F, 96 (33%) calreticulin, 9 (3%) myeloproliferative leukemia virus oncogene gene mutation-positive and 30 triple-negative (11%) cases were identified, while in primary myelofibrosis 56 (57%) Janus kinase 2 V617F, 25 (25%) calreticulin, 7 (7%) myeloproliferative leukemia virus oncogene gene mutation-positive and 11 (11%) triple-negative cases were identified. Patients positive for the calreticulin mutation were younger and had higher platelet counts compared to Janus kinase 2 mutation-positive counterparts. Calreticulin mutation-positive patients with essential thrombocythemia showed a lower risk of developing venous thrombosis, but no difference in overall survival. Calreticulin mutation-positive patients with primary myelofibrosis had a better overall survival compared to that of the Janus kinase 2 mutation-positive (P=0.04) or triple-negative cases (P=0.01). Type 2 calreticulin mutation occurred more frequently in essential thrombocythemia than in primary myelofibrosis (P=0.049). In essential thrombocythemia, the calreticulin mutational load was higher than the Janus kinase 2 mutational load (P<0.001), and increased gradually in advanced stages. Calreticulin mutational load influenced blood counts even at the time point of diagnosis in essential thrombocythemia. We confirm that calreticulin mutation is associated with distinct clinical characteristics and explored relationships between mutation type, load and clinical outcome

The disappearance and reappearance of optical emission lines and the drop in a Swift/XRT count rate during the recent rebrightening of TCP J21040470+4631129

We report the results of our continuing optical and X-ray monitoring of the bright WZ Sge-type dwarf nova TCP J21040470+4631129 (hereafter TCP2104) discovered on July 12, 2019 (for previous reports, see ATel #12947, #13009). Our optical photometric observations are mostly performed using 30-cm class telescopes, while spectroscopic data are obtained with the 2.1-m telescope at the OAN-SPM, the 2.5-m Isaac Newton Telescope on La Palma, and other smaller telescopes.peer-reviewe